Company intelligence / Profile preview

Eris Biotech

American Fork, Utah, United Stateserisbio.com ↗

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Eris Biotech is developing small molecule hypoxia-activated prodrugs that only become active within the low oxygen environment characteristic of most solid tumors. Their lead program targets mesothelioma by blocking tumor-stroma communication and engaging the immune system. The approach aims to maximize anti-tumor efficacy while minimizing systemic toxicity. No clinical results have been reported as programs are pre-clinical.

Therapeutic areas: Oncology
Modalities: Small moleculeHypoxia-activated prodrug (HAP)
Industry: Biotech

Drug pipeline

1 asset

Eris Biotech immune-evasion inhibitor

Preclinical

Partnerships

No major partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Eris Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eris Biotech.

Explore the full profile